Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: A long-term observational prospective study

Arthritis Research and Therapy

Volumn 12, Issue 6, 2010, Pages

  Laskari, Katerina ^a   Mavragani, Clio P ^a   Tzioufas, Athanasios G ^a   Moutsopoulos, Haralampos M ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; MESNA; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ONDANSETRON; STEROID; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ADOLESCENT; ADULT; ALOPECIA; AMENORRHEA; ARTICLE; BONE MARROW TOXICITY; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DISEASE ACTIVITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HEMORRHAGIC CYSTITIS; HERPES ZOSTER; HUMAN; HYPERCHOLESTEROLEMIA; INFECTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MALE; MYOCARDITIS; NAUSEA; REMISSION; SINUSITIS; SURVIVAL TIME; ULCERATIVE COLITIS; VAGINA MYCOSIS; VOMITING; CLINICAL TRIAL; MIDDLE AGED; PROSPECTIVE STUDY; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; TIME; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78049507460     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3184     Document Type: Article

References (34)

1. Appel GB, Cohen DJ, Pirani CL, Meltzer JI, Estes D. Long-term follow-up of patients with lupus nephritis: a study based on the classification of the World Health Organization. Am J Med 1987, 83:877-885. 10.1016/0002-9343(87)90645-0, 3674094.
2. Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, Vaughan EM, Kuroiwa T, Danning CL, Steinberg AD, Klippel JH, Balow JE, Boumpas DT. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001, 135:248-257.
3. Austin HA, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, Decker JL. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986, 314:614-619. 10.1056/NEJM198603063141004, 3511372.
4. Ioannidis JPA, Katsifis GE, Tzioufas AG, Moutsopoulos H. Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus. J Rheumatol 2002, 29:2129-2135.
5. Dooley MA, Hogan S, Jennette C, Falk R. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int 1997, 51:1188-1195. 10.1038/ki.1997.162, 9083285.
6. Ioannidis JP, Boki KA, Katsorida ME, Drosos AA, Skopouli FN, Boletis JN, Moutsopoulos HM. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000, 57:258-264. 10.1046/j.1523-1755.2000.00832.x, 10620207.
7. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido E, Ede R, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis triala randomized trial of low-dose versus high dose intravenous cyclophosphamide. Arthritis Rheum 2002, 46:2121-2131. 10.1002/art.10461, 12209517.
8. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, Abramovicz D, Blockmans D, Cauli A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010, 69:61-64. 10.1136/ard.2008.102533, 19155235.
9. Kapitsinou PP, Boletis JN, Skopouli FN, Boki KA, Moutsopoulos HM. Lupus nephritis: treatment with mycophenolate Mofetil. Rheumatology (Oxford) 2004, 43:377-380. 10.1093/rheumatology/keh012, 14963204.
10. Chan TM, Li FK, Tang CS, Mok MY, Li FK, . Hong Kong Nephrology Study Group Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000, 343:1156-1162. 10.1056/NEJM200010193431604, 11036121, Hong Kong Nephrology Study Group.
11. Chan TM, Tse KC, Tang CS, Mok MY, Li FK, . Hong Kong Nephrology Study Group Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005, 16:1076-84. 10.1681/ASN.2004080686, 15728784, Hong Kong Nephrology Study Group.
12. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005, 353:2219-2228. 10.1056/NEJMoa043731, 16306519.
13. Cortés-Hernández J, Torres-Salido MT, Medrano AS, Tarrés MV, Ordi-Ros J. Long-term outcomes--mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. Nephrol Dial Transplant 2010, 25:3939-3948. 10.1093/ndt/gfq322, 20538787, 20538787.
14. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D, . Aspreva Lupus Management Study Group Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009, 20:1103-1112. 10.1681/ASN.2008101028, 2678035, 19369404, Aspreva Lupus Management Study Group.
15. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P, Roth D. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004, 350:971-980. 10.1056/NEJMoa031855, 14999109.
16. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004, 15:241-250. 10.1097/01.ASN.0000108969.21691.5D, 14747370.
17. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25:1271-1277. 10.1002/art.1780251101, 7138600.
18. Vitali C, Bencivelli W, Isenberg DA, Smolen JS, Snaith ML, Sciuto M, Neri R, Bombardieri S. Disease activity in systemic lupus erythematosus: report of the consensus study group of the European workshop for rheumatology research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. Clin Exp Rheumatol 1992, 10:541-547.
19. Austin HA, Muenz LR, Joyce KM, Antonovych TT, Balow JE. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984, 25:689-695. 10.1038/ki.1984.75, 6482173.
20. Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006, 54:421-432. 10.1002/art.21625, 16453282, Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria.
21. Kasitanon N, Fine DM, Haas M, Magder LS, Petri M. Estimating renal function in lupus nephritis: comparison of the Modification of Diet in Renal Disease and Cockcroft Gault equations. Lupus 2007, 16:887-895. 10.1177/0961203307084167, 17971362.
22. Kreuter A, Tomi NS, Weiner SM, Huger M, Altmeyer P, Gambichler T. Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy. Br J Dermatol 2007, 156:1321-1327. 10.1111/j.1365-2133.2007.07826.x, 17408395.
23. Karim MY, Alba P, Cuadrado MJ, Abbs IC, D'Cruz DP, Khamashta MA, Hughes GR. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford) 2002, 41:876-882. 10.1093/rheumatology/41.8.876, 12154204.
24. Vasoo S, Thumboo J, Fong KY. Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil. Lupus 2003, 12:630-632. 10.1191/0961203303lu417cr, 12945723.
25. Mak A, Mok CC. Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus. Lupus 2005, 14:856-858. 10.1191/0961203305lu2163cr, 16302683.
26. Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley MA, . ALMS Group Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenterprospectiverandomizedopen-labelparallel-group clinical trial. Arthritis Rheum 2010, 62:211-221. 10.1002/art.25052, 20039429, ALMS Group.
27. Katsifis GE, Tzioufas AG, Vlachoyiannopoulos PG, Voulgarelis M, Moutsopoulos HM, Ioannidis JP. Risk of myelotoxicity with intravenous cyclophosphamide in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2002, 41:780-786. 10.1093/rheumatology/41.7.780, 12096228.
28. Sahin GM, Sahin S, Kiziltas S, Masatlioglu S, Oguz F, Ergin H. Mycophenolate mofetil versus azathioprine in the maintenance therapy of lupus nephritis. Ren Fail 2008, 30:865-869. 10.1080/08860220802353843, 18925525.
29. Laskari K, Zintzaras E, Tzioufas AG. Ovarian function is preserved in women with severe systemic lupus erythematosus after a 6-month course of cyclophosphamide followed by mycophenolate mofetil. Clin Exp Rheumatol 2010, 28:83-86.
30. Mok CC, Ho CT, Siu YP, Chan KW, Kwan TH, Lau CS, Wong RW, Au TC. Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens. Am J Kidney Dis 2001, 38:256-264. 10.1053/ajkd.2001.26084, 11479150.
31. Gourley MF, Austin HA, Scott D, Yarboro CH, Vaughan EM, Muir J, Boumpas DT, Klippel JH, Balow JE, Steinberg AD. Methylprednisolone and cyclophosphamidealone or in combinationin patients with lupus nephritis. A randomizedcontrolled trial. Ann Intern Med 1996, 125:549-557.
32. Boumpas DT, Austin HA, Vaughn EM, Klippel JH, Klippel JH, Steinberg AD, Yarboro CH, Balow JE. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992, 340:741-745. 10.1016/0140-6736(92)92292-N, 1356175.
33. Moroni G, Quaglini S, Maccario M, Banfi G, Ponticelli C. "Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 1996, 50:2047-2053. 10.1038/ki.1996.528, 8943489.
34. Chen YE, Korbet SM, Katz RS, Schwartz MM, Lewis EJ, . for the Collaborative Study Group Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 2008, 3:46-53. 10.2215/CJN.03280807, 2390978, 18003764, for the Collaborative Study Group.